Nav: Home

For HIV with substance use, patient navigation, incentives not enough to improve outcomes

July 12, 2016

A new study funded by the National Institute on Drug Abuse of the National Institutes of Health found that among hospitalized patients with HIV infection and substance use, patient navigation (care coordination with case management) and the use of financial incentives did not have a beneficial effect on suppressing HIV after 12 months, compared to treatment as usual.

The research will be published in the July 12 issue of JAMA, and was conducted by a research team from Columbia University's Mailman School of Public Health, Emory University and the University of Miami.

At Emory, lead researchers were Carlos del Rio, MD, professor of medicine at Emory University School of Medicine and chair of the Hubert Department of Global Health at Rollins School of Public Health, and Wendy Armstrong, MD, professor of medicine at Emory School of Medicine and medical director of the Ponce de Leon Center in Atlanta, which houses the Grady Health System Infectious Disease Program.

The U.S. National HIV/AIDS Strategy calls for improved engagement in care and increased viral suppression for people living with HIV. Yet it has been estimated that only 30 percent of the 1.2 million people with HIV infection in the United States in 2011 were virally suppressed, and research conducted from 1999-2007 found that many were hospitalized with conditions preventable through HIV treatment.

The study enrolled 801 patients with HIV infection and substance use from 11 hospitals across the United States from July 2012 through January 2014. Participants were randomly assigned to receive patient navigation alone, patient navigation plus financial incentives, or treatment as usual. HIV-1 plasma viral load was measured at baseline and at six and 12 months.

Patient navigation included up to 11 sessions of care coordination with case management and motivational interviewing techniques over six months. Financial incentives (up to $1,160) were provided for achieving targeted behaviors aimed at reducing substance use, increasing engagement in HIV care, and improving HIV outcomes. Treatment as usual was the standard practice at each hospital for linking hospitalized patients to outpatient HIV care and substance use disorders treatment.

Investigators found that at the end of 12 months around 35 percent of the patients were virally suppressed with no significant differences in rates of HIV viral suppression or death among the three groups.

According to the paper's authors, there are several possible explanations for the lack of positive results. Participation in treatment for substance use disorders was low across groups, with no decrease in overall substance use and severity of use. Although patient navigators sought to engage participants with available treatment services, several study sites were not in areas with available substance use treatment services.

Also, many study participants had multiple comorbidities in addition to substance use disorders, including poverty, racism, unstable housing, HIV-related stigma, and high rates of incarceration.

The authors note that the trial cannot rule out the possibility that financial incentives and patient navigation may be effective interventions for individuals already engaged in substance use disorders.

"Our study shows that intensive, individual interventions are not sufficient to improve HIV outcomes among people not already benefiting from treatment, and other approaches are needed for this vulnerable population," says del Rio.

"Substance use is a significant factor in poor HIV clinical outcomes, and it is essential that we continue to address this issue and overcome barriers to engaging patients in substance use treatment if we expect to control the HIV epidemic," says Armstrong. "This includes confronting the co-morbidities associated with considerable social disadvantage that often accompany this disease."
-end-
The study was funded by the National Institute on Drug Abuse, and at Emory additionally by the Emory Center for AIDS Research (P30AI050409) and the Atlanta Clinical and Translational Science Institute (UL1TR000454).

Emory Health Sciences

Related Hiv Articles:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.
The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).
Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.
Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.
The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.
The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.
Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.
NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.
Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.
More HIV News and HIV Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

How to Win Friends and Influence Baboons
Baboon troops. We all know they're hierarchical. There's the big brutish alpha male who rules with a hairy iron fist, and then there's everybody else. Which is what Meg Crofoot thought too, before she used GPS collars to track the movements of a troop of baboons for a whole month. What she and her team learned from this data gave them a whole new understanding of baboon troop dynamics, and, moment to moment, who really has the power.  This episode was reported and produced by Annie McEwen. Support Radiolab by becoming a member today at Radiolab.org/donate.